Tag Archives: pharmaceutical pricing

Value-Based Pricing of New Technologies

13 Aug
price and value balance sign

Health insurance companies and governments use strong financial and administrative barriers to manage the utilization of new technologies. Cost-sharing (co-insurance or co-payments), prior authorization, clinical panel reviews, therapeutic reference pricing, and new technology appraisals are designed to manage the incremental uptake of new technologies. These technologies, for example, PCSK-9 inhibitors and enzyme replacement therapies, are […]

Market Access Landscape in the Middle East:The Next Five Years

06 Jun
Middle-East

The market access landscape in the Middle East is changing rapidly. The growth of private health insurance markets in the Gulf is a significant catalyst for the re-organisation of private sector stakeholders and improvements in internal reimbursement policies. In the past, Payors were relatively generous in their reimbursement of new technologies, but in the next […]

WHO’s serious reservations on Value-Based Pricing: Conflicts and Nuances

08 Jun
WHO Fair Pricing Forum Carapinha & Company

On May 10 and 11, the WHO Fair Pricing Forum met to discuss improvements to medicine pricing practices and pricing approaches that balance public health needs and incentives for pharmaceutical research and development. The Forum was established to facilitate the exchange of insights on fairer medicine pricing systems, identification of research gaps to support improvements, […]

En garde QALY! Is your end nigh?

05 Apr
qalys

The Spanish Ministry of Health recently rejected the use of QALYs in cost-effectiveness analyses. At issue is the subjective nature of the parameters used to develop the QALY. The Quality-Adjusted Life-Years (QALY) is a product of the change in utilities associated with a treatment multiplied by the time of treatment exposure. The QALYs gained combined […]

Comment on the implications of external price referencing of pharmaceuticals in Middle East countries

15 Aug

Expert Review of Pharmacoeconomics & Outcomes Research Corresponding Author: Dr. João L. Carapinha, Ph.D External Price Referencing (EPR) is frequently used by countries to control pharmaceutical prices but studies to substantiate its use in the Middle East (ME) is lacking. The paper by Kalo et al set-out to fill this lacuna through three objectives: i) […]

A Comparative Review of the Pharmacoeconomic Guidelines in South Africa

15 Aug

Journal of Medical Economics Author: Dr. João L. Carapinha, Ph.D. Objective: To compare the pharmacoeconomic guidelines in South Africa (SA) with other middle- and high-income countries. Methods: A comparative review of key features of the pharmacoeconomic guidelines in SA was undertaken using the Comparative Table of Pharmacoeconomic Guidelines developed by the International Society of Pharmacoeconomics […]

Carapinha Logo